A bioassay of technical-grade @entity11910 for possible carcinogenicity was conducted using Osborne-Mendel @entity35 and B6C3F1 @entity19 . @entity11910 in @entity4336 oil was administered by gavage, at either of two dosages, to groups of 50 male and 50 female animals of each species, 5 days a week for a period of 78 weeks, followed by an observation period of up to 35 weeks for @entity35 and up to 13 weeks for @entity19 . The high and low time-weighted average dosages of @entity11910 were, respectively, 92 and 46 mg/kg/day for male and female @entity35 , and 390 and 195 mg/kg/day for the male and female @entity19 . For each species, 20 animals of each sex were placed on test as vehicle controls. These animals were gavaged with @entity4336 oil at the same rate as the high dose group of the same sex. Twenty animals of each sex were placed on test as untreated controls for each species. These animals were not intubated. No @entity5 were observed at statistically significant incidences in male or female @entity35 . In both male and female @entity19 , administration of @entity11910 was associated with a significantly increased incidence of @entity157 . @entity157 were observed in 2/17 (12 percent) untreated control males, 2/20 (10 percent) vehicle control males, 18/49 (37 percent) low dose males, and 37/49 (76 percent)high dose males. @entity157 were also observed in 2/20 (10 percent) untreated control females, 0/20 vehicle control females, 16/48 (33 percent) low dose females, and 40/45 (89 percent) high dose females. Both the Fisher exact test comparing @entity5 incidences of dosed to control groups and the Cochran-Armitage test for positive dose-related trend indicated a highly significant (P<0.001) association between @entity157 in all @entity19 groups and the administration of @entity11910 . A positive dose-related association between administration of @entity11910 and the incidence of @entity10163 was indicated by the Cochran-Armitage test for @entity19 of both sexes. Fisher exact tests confirmed these results for high dose female @entity19 but not for other @entity19 groups. There were no other @entity5 for which statistical tests indicated a positive association between dosage and @entity5 incidence in @entity19 . The results of this study do not provide convincing evidence for the carcinogenicity of @entity11910 in Osborne-Mendel @entity35 . Under the conditions of this bioassay @entity11910 is carcinogenic in B6C3F1 @entity19 , causing @entity157 and @entity1911 .

Bioassay of XXXX for possible carcinogenicity.

@entity11910 :: ('MESH:C024567', 'Chemical') :: ['1,1,2-trichloroethane', '1,1,2-Trichloroethane'] @entity1911 :: ('MESH:D010673', 'Disease') :: ['adrenal pheochromocytomas'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasms'] @entity4336 :: ('381124', 'Species') :: ['corn'] @entity10163 :: ('MESH:D000307', 'Disease') :: ['pheochromocytoma of the adrenal gland'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity157 :: ('MESH:D006528', 'Disease') :: ['Hepatocellular carcinomas', 'hepatocellular carcinomas']
@entity11910 :: (MESH:C024567,Chemical) :: ['1,1,2-trichloroethane']
